成人原发性脊髓胶质母细胞瘤的分子特征与临床结局:一项系统综述
该系统综述检索2013年1月1日至2023年10月14日PubMed、Embase和CENTRAL数据库,纳入31篇论文共71例成人原发性脊髓胶质母细胞瘤患者。多数患者位于亚洲(53%)和美国(23%),中位年龄32岁,61%为男性,肿瘤主要位于胸段(42%)。中位总生存期10个月,中位无进展生存期7个月;接受放疗联合替莫唑胺治疗的患者无进展生存期显著更高(中位15个月 vs 4.5个月,95%CI -1.32至22.56,p<0.05)。
要点
- 成人原发性脊髓胶质母细胞瘤罕见,多位于胸段,常见运动缺陷(92%)和感觉缺陷(86%)。
- 分子特征与颅内胶质母细胞瘤相似:MGMT启动子甲基化增加40%,TERT突变50%,野生型TP53突变减少41%。
- 放疗联合替莫唑胺组中位无进展生存期15个月,显著高于未联合组的4.5个月(p<0.05)。
核心结论
- 原发性脊髓胶质母细胞瘤仍是一种罕见疾病,治疗方式存在显著差异,可能受地理可及性影响。
- 与颅内胶质母细胞瘤相比,观察到的分子特征强调需要进一步基因组验证和数据收集。
- 克服全切除挑战的手术进展可能有助于改善总生存期。
研究设计与样本
- 遵循PRISMA指南的系统文献综述,检索PubMed、Embase和CENTRAL数据库(2013年1月1日至2023年10月14日)。
- 纳入标准为英文、人类、组织学确诊的原发性脊髓胶质母细胞瘤,排除滴状转移。
- 共纳入31篇论文,报告71例成人原发性脊髓胶质母细胞瘤患者。
主要发现
- 患者多数位于亚洲(53%)和美国(23%),中位年龄32岁(范围24-47岁),61%为男性。
- 肿瘤主要位于胸段(42%);临床表现包括运动缺陷(92%)、感觉缺陷(86%)、颈/背痛(68%)和肠道/膀胱功能障碍(59%)。
- 手术方式为次全切除(51%)、全切除(23%)和活检(26%);术后辅助治疗多数为外照射放疗联合替莫唑胺(66%),17%接受无辅助治疗的姑息治疗。
- 分子特征:MGMT启动子甲基化增加40%,TERT突变50%,野生型TP53突变减少41%。
- 中位总生存期10个月(范围6-18个月),中位无进展生存期7个月(范围3-10个月);放疗联合替莫唑胺组中位无进展生存期15个月 vs 4.5个月(95%CI -1.32至22.56,p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Primary spinal cord glioblastoma (scGB) is a rare and aggressive spinal glioma, making up 7.5% of such cases. Whereas molecular profiles associated with improved overall survival (OS) are well studied for cranial glioblastoma (GB), the molecular characteristics of scGB are less documented. This review sought to document the molecular signatures of scGB, explore current treatment strategies, and evaluate clinical outcomes. METHODS: A systematic literature review following the PRISMA guidelines searched the PubMed, Embase, and CENTRAL databases (January 1, 2013, to October 14, 2023) using glioblastoma-, spine-, and genetics-related keywords. Inclusion criteria were English-language articles on humans with histologically confirmed primary scGB, excluding drop metastases. Data on demographic characteristics, treatments, molecular profile, and outcome were extracted. RESULTS: Over 10 years, 71 patients with adult primary scGB were reported in 31 papers. Most patients were located in Asia (53%) and the United States (23%). The median (range) age was 32 (24-47) years, with 61% of patients male. Tumors occurred primarily in the thoracic region (42%). Clinical presentation included motor deficits (92%), sensory deficits (86%), neck/back pain (68%), and bowel/bladder dysfunction (59%). Patients underwent subtotal resection (51%), gross-total resection (GTR) (23%), and biopsy (26%). Postoperative adjuvant treatment included concomitant external beam radiation therapy (XRT) and temozolomide (TMZ) in the majority of cases (66%), as well as palliative care without adjuvant treatment (17%). The molecular signature of scGB was similar to its cranial counterpart in terms of MGMT-promoter methylation (40% increased methylation) and higher for mutant TERT (50%) but decreased for wild-type tumor protein p53 (41% decreased mutation). Median (range) OS was 10 (6-18) months, and median progression-free survival (PFS) was 7 (3-10) months. PFS was significantly higher in patients treated with XRT/TMZ: median 15 months vs 4.5 months (95% CI -1.32 to 22.56, p < 0.05). CONCLUSIONS: Primary scGB remains a rare disease with notable variations in treatment, potentially influenced by geographical availability. The observed molecular profile, when compared to that of cranial GB, emphasizes the need for further genomic validation and data collection. Surgical advancements to overcome the challenges of accomplishing GTR may contribute to improved OS.
引用
- Ezzat B, Young T, Schüpper AJ, et al. Molecular profile and clinical outcome of adult primary spinal cord glioblastoma: a systematic review. J Neurosurg Spine. 2024. PMID: 39059422. doi:10.3171/2024.4.SPINE231350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。